CardiAI is developing an advanced point-of-care diagnostic platform that integrates a colloidal gold-based NT-proBNP lateral flow assay with a quantitative reader and mobile app. This system utilizes gold nanoparticle–antibody conjugates to achieve high sensitivity and specificity in detecting NT-proBNP, a key biomarker for heart failure and cardiac dysfunction. The test provides results within 10–15 minutes, enabling immediate clinical decision-making. Its simple and user-friendly format makes it suitable for use in emergency departments, clinics, and even at home. The quantitative reader is designed to convert the test strip’s colorimetric signal into a precise NT-proBNP concentration, supporting accurate and quantitative interpretation. Results are tracked and managed via an integrated mobile app, which enables longitudinal monitoring and supports remote healthcare management.